


# The WIN Consortium in Precision Oncology

www.winconsortium.org



WIN was formed on the premise that Consortium members can accomplish together what no single institution or group of patients can do alone.

WIN was founded in France as a non-profit by **Dr. John Mendelsohn**, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and **Prof. Thomas Tursz**, General Director Gustave Roussy, France.

**BOLD MISSION** Significantly improve survival of cancer patients across the world through international collaboration.

**STRATEGY:** Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

## WIN History

**John Mendelsohn**, Past President MD Anderson Cancer Center, Houston, USA

Chair, WIN 2010 - 2018



**Thomas Tursz**, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2010 - 2012, 2016 - 2018



**Alexander Eggermont**, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2012 - 2016



**Josep Tabernero**, Head Vall d'Hebron Institute of Oncology, Barcelona, Spain

Vice-Chair, WIN 2018 - 2023



**Richard L. Schilsky**, Past President, former Executive VP and Chief Medical Officer, ASCO, USA

Chair, WIN 2018 - 2023



**Wafik El-Deiry**, Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, USA

Chair, WIN 2024 -



## WIN Executive Committee



**Catherine Bresson**  
Director, Operational Team, WIN Consortium



**Wafik El-Deiry**  
Chair, WIN Consortium; Director, Legorreta Cancer Center at Brown University (USA)



**Razelle Kurzrock**  
Chief Medical Officer, WIN Consortium; Prof. of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision Oncology (USA)



**Yves A. Lussier**  
Chairman, Scientific Advisory Board, WIN Consortium; Professor and Chair, Department of Biomedical Informatics, The University of Utah School of Medicine (USA)



**Jacques Raynaud**  
Senior adviser to WIN Strategy, Science and Fundraising, WIN Consortium



**Richard L. Schilsky**  
Chair Emeritus, WIN Consortium; Professor Emeritus, University of Chicago; past President and former Executive Vice President & Chief Medical Officer (ASCO) (USA)



**Marina Sekacheva**  
Head of the Membership Committee, WIN Consortium; Director of Personalized Oncology Institute, I.M. Sechenov First Moscow State Medical University, Sechenov University (Russia)

## Publications

### WINTHER trial results

J. Rodon et al., Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nature Medicine* volume 25, pages 751-758 (2019)

### Simplified interventional mapping system (SIMS)

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

Solomon B, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. *Cancer Med*. (2022) ;00:1-11

### Digital Display Precision Predictor (DDPP)

Lazar, V., et al., Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (2021) *npj Precis. Onc.* 5, 33.

Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies *JCO Precision Oncology* no. 6 (2022) e2200072. Published online

Lazar, V., et al., Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. *Therapeutic Advances in Medical Oncology* (2022), Vol. 14: 1-15

Lazar, V., et al., A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. *Ther Adv Med Oncol* (2023), Vol. 15: 1-15

# WIN 34 Members across the Globe

## Academic Institutions in Americas



## Academic Institutions in Asia-Pacific



## Academic Institutions in Europe



## Small & Medium Enterprises



## Non-Profit Organizations



World-class academic medical centers SME (3), research and patient advocate organizations (4).

34 members in 18 countries and 5 continents  
Access to > 5,000,000 patients  
[www.winconsortium.org](http://www.winconsortium.org)




## WIN Value Proposition

- ❑ Access to:
  - Global thought leaders in Precision Oncology
  - Platform of leading cancer centers across the world → rapid accrual/diversity of population
- ❑ Expertise in genomics and transcriptomics
- ❑ Experience and success with:
  - Complex biomarker-directed clinical trials (WINTHER trial)
  - Obtaining high quality tissues and bloods for comprehensive omics
  - Managing international multi-site trials
  - International Molecular Tumor Board
- ❑ Ability to partner with companies and philanthropic organizations or individuals to perform Precision Oncology studies to:
  - Better identify treatment options for patients including optimal dosing of novel combination therapies
  - Understand mechanisms of resistance to cancer therapy
  - Improve patients' treatment follow-up and early diagnosis non-invasively
  - Accelerate drug development through better patient selection

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

El-Deiry, et al., Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing Next-Generation Precision Oncology to Patients. *Oncotarget*. 2025; 16:140-162

A Hernando-Calvo, et al., Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment *Oncotarget*. 2025; 16:456-466.  
O. Landau, et al. OncoAID: An Open Access Targeted Anti-Cancer Database *Front. Pharmacol.*, 13 August 2025 Sec. Pharmacology of Anti-Cancer Drugs Volume 16 - 2025



WIN's 14th symposium by co-chairs Prof. W El-Deiry and Dr. R Kurzrock in a series of remarkable symposia. 3-4 Oct 2025, Philadelphia, US in cooperation with the 2<sup>nd</sup> conference of APM with Nobel Laureate Dr. William G. Kaelin Jr. (Harvard Medical School, Dana-Farber Cancer Institute)

## **WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East**

### **A Vision for WIN's Future**

- ☐ Expand the WIN membership with additional:
  - World-class cancer centers in US and across the globe
  - Diagnostics, AI, pharma companies, patient-advocacy organizations, non-profits
- ☐ Leveraging WIN's platform for global academic members to:
  - Partner with companies for compelling Precision Oncology and Early Diagnosis studies across the globe
  - Build upon transcriptomics' experience acquired in international clinical trials like WINTHER and others that have so much potential → incorporating Functional Precision Medicine assays and novel modalities
  - Accelerate trial results delivery and simplify management of multi-site international trials
- ☐ Leverage WIN IP (algorithm for patient's treatment matching and patient stratification)
- ☐ New initiatives such as international Molecular Tumor Board
- ☐ Involve WIN's exceptional SAB - Innovation and Collaboration globally to ensure continued success
- ☐ Strengthen relationships with professional societies (ACS, ASCO, AACI, AACR, etc.)

### **Membership Benefits**

- ☐ Representation at international General Assembly (right to vote on all decisions)
- ☐ Access to governance positions (2-year mandates)
- ☐ Ability to participate in WIN Committees and International Molecular Tumor Board for faculty
- ☐ Ability to participate in WIN-managed studies
- ☐ Ability to propose studies to be performed in WIN member institutions, but no obligation
- ☐ Each project is subject to contract negotiated in good faith. Usual IP rules apply
- ☐ Each project needs a separate funding mechanism. All participants in studies required to participate in the effort
- ☐ Visibility on website, symposia

#### **Annual Membership Dues**

Academics: From 5,000 to 50,000 € depending on research budget  
Industries: Pharma 250,000 € ; Technology partners 100,000 €



## Committees

### Active Committees

- ☐ International Molecular Tumor Board with Precision Oncology experts from 18 countries  
Discussing complex clinical cases with a focus on tailored combinations. Cases are being published.



- ☐ Membership Committee
- ☐ Symposium Committee
- ☐ Publication Committee
- ☐ Data Science Committee

### Planned Committees

- ☐ Rare cancers committee
- ☐ Radiation Precision Oncology Committee
- ☐ Regulatory Issues in Precision Oncology Committee
- ☐ Novel Agents Committee
- ☐ Novel tissue agnostic biomarkers Committee
- ☐ Living Guidelines Committee
- ☐ Disease Committees (Thoracic, GI, GU, CNS, Breast Gyn cancers)